Биохимия и фармакология: открытый доступ

Биохимия и фармакология: открытый доступ
Открытый доступ

ISSN: 2167-0501

Абстрактный

Efficacy and Safety of Atorvastatin in Dyslipidemic Patients at Tertiary Care Hospital

Santosh Shukla, Ganachari MS, Jayaprakash Appajigol, Geetanjali Salimath, Saurabh Gaur and Vaneeta Dhyani

Aims: The objective of the study was to assess the safety, effectiveness and Adherence of morning versus evening atorvastatin administration in dyslipidemic Patients.
Settings and design: A comparative study conducted at KLE’s Dr. Prabhakar Kore Charitable Hospital & Medical Research Centre; Department of Medicine; Belagavi, Karnataka, India.
Methods and material: Patients who were prescribed atorvastatin 40 mg p.o. daily by their physician were interviewed by clinical pharmacist for study enrolment. Patients were excluded if they had any history diseases or medication known to effect serum lipid levels, blood samples were collected after overnight fasting period and serum lipid levels were measured at 4th and 8th week.
Statistical analysis used: Paired t-test; SPSS version 20.0
Results: 85 male patients (83.3%) and 17 (16.6%) female patients with a mean ± S.D. age of 56.72 ± 10.09 years were enrolled into the study. All patients were receiving atorvastatin in the evening, after four week the same patients were changed to morning dose. No significant change in lipid values measured were found between morning and evening administration after 8 weeks. There were no difference in the incidence of clinical adverse reactions among the morning and evening regimen.
Conclusions: Atorvastatin 40 mg was found to be safe and effective regardless of the time of drug administration i.e. morning versus evening without much change in the levels of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. On the contrary, significant adherence levels increased with morning administration than evening which may contribute to increase in compliance.

Отказ от ответственности: Этот тезис был переведен с использованием инструментов искусственного интеллекта и еще не прошел рецензирование или проверку.
Top